PreludeDx was founded to deliver actionable tools to manage early stage breast cancer.
PreludeDx's first diagnostic test, DCISionRT is the result of over a decade of research and development focused on DCIS. PreludeDx began developing its DCIS test in 2009 after licensing technology from University of California, San Francisco. DCISionRT’s technology was designed from the beginning to address the critical question faced by patients with DCIS. What is my risk of recurrence and what treatment is appropriate?
PreludeDx's first diagnostic test, DCISionRT is the result of over a decade of research and development focused on DCIS. PreludeDx began developing its DCIS test in 2009 after licensing technology from University of California, San Francisco. DCISionRT’s technology was designed from the beginning to address the critical question faced by patients with DCIS. What is my risk of recurrence and what treatment is appropriate?
Location: United States, California, Laguna Hills
Employees: 11-50
Phone: 1.888.211
Total raised: $20M
Founded date: 2009
Investors 2
| Date | Name | Website |
| - | BlueStone ... | bluestonev... |
| 02.04.2022 | Evidity He... | evidity.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.03.2022 | - | $20M | - |
Mentions in press and media 10
| Date | Title | Description |
| 25.06.2026 | Eckuity Capital Launches Fund II and Backs Automata Technologies | Eckuity Capital, a North American healthcare growth equity firm, today announced the first close of Eckuity Capital Fund II and the fund’s inaugural investment, leading the Series C of Automata Technologies alongside Danaher, a global scien... |
| 31.10.2022 | GenesisCare and PreludeDx(TM) present compelling Australian-first DCISionRT Study Interim Analysis during Breast Cancer Awareness Month 45% change in treatment recommendations when using DCISionRT | CALIFORNIA CITY, Calif., Oct. 31, 2022 /PRNewswire/ -- GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation (PreludeDx(TM)), a leader in molecular diagnostics and precision medicine, today announced in... |
| 02.02.2022 | PreludeDx™ Announces the Appointment of Derek J. Maetzold of Castle Biosciences to its Board of Directors | LAGUNA HILLS, Calif., Feb. 2, 2022 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that it has appointed Derek J. Maetzold, Founder, P... |
| 29.09.2021 | PreludeDx : Appoints Dr. Karuna Mittal, Director, Research and Development | LAGUNA HILLS, Calif., Sept. 29, 2021 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today the addition of Karuna Mittal, Ph.D. as Director ... |
| 04.06.2021 | DCISionRT by PreludeDx Identifies Women with DCIS with Unacceptably High Rates of Local Recurrence after Breast Conserving Surgery and Radiation Therapy | |
| 04.03.2021 | DCISionRT® by PreludeDx™ Identifies DCIS Breast Cancer Patients at Increased Risk for Breast Cancer Specific Death | |
| 08.12.2020 | DCISionRT® by PreludeDx™ Identifies Subset of RTOG 9804 Low Risk Criteria DCIS Patients Who Experienced 84% Relative Benefit with Radiation | |
| 24.11.2020 | PreludeDx™ Announces Partnership with America's Choice Provider Network | |
| - | Fourth Validation of DCISionRT by PreludeDx Predicts Risk of Breast Cancer Recurrence and Radiation Benefit for DCIS Patients after Surgery | LAGUNA HILLS, Calif., March 18, 2021 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early stage breast cancer, presented data at the Society of Surgical Oncology (SSO) 2021 Int... |
| - | DCISionRT® by PreludeDx™ Identifies DCIS Breast Cancer Patients at Increased Risk for Breast Cancer Specific Death | LAGUNA HILLS, Calif., March 4, 2021 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early stage breast cancer, presented data at the Miami Breast Cancer Conference (MBCC) 2021 A... |